<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Drug Deliv.</journal-id>
<journal-title>Frontiers in Drug Delivery</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Drug Deliv.</abbrev-journal-title>
<issn pub-type="epub">2674-0850</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1221628</article-id>
<article-id pub-id-type="doi">10.3389/fddev.2023.1221628</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Drug Delivery</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Epithelium dynamics differ in time and space when exposed to the permeation enhancers penetramax and EGTA. A head-to-head mechanistic comparison</article-title>
<alt-title alt-title-type="left-running-head">Panou et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fddev.2023.1221628">10.3389/fddev.2023.1221628</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Panou</surname>
<given-names>D. A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2239226/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pedersen</surname>
<given-names>S. F.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/91326/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kristensen</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1286221/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nielsen</surname>
<given-names>H. M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/685639/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Center for Biopharmaceuticals and Biobarriers in Drug Delivery (BioDelivery), Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Section for Cell Biology and Physiology, Department of Biology, Faculty of Science, University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>CNS Drug Delivery and Barrier Modelling, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2057503/overview">Sam Maher</ext-link>, Royal College of Surgeons in Ireland, Ireland</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/830819/overview">Fiona McCartney</ext-link>, University College Dublin, Ireland</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1305374/overview">Hisanao Kishimoto</ext-link>, Tokyo University of Pharmacy and Life Sciences, Japan</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: H. M. Nielsen, <email>hanne.morck@sund.ku.dk</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>3</volume>
<elocation-id>1221628</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>05</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>07</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Panou, Pedersen, Kristensen and Nielsen.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Panou, Pedersen, Kristensen and Nielsen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Absorption of therapeutic peptides like glucagon-like peptide or insulin for diabetes therapy upon oral administration is highly restricted by the tight junction (TJ) proteins interconnecting the cells comprising the intestinal epithelium. An approach to improve transepithelial permeation of such biopharmaceuticals via the paracellular pathway is to use functional excipients, which transiently modulate the TJs. Here, we investigated the membrane-interacting peptide, penetramax, and the divalent cation chelator, ethylene glycol tetraacetic acid (EGTA) at different concentrations, to reveal and compare their cellular modes of action when increasing the transepithelial permeation of drug macromolecules. The epithelial integrity was studied in real time along with dextran permeation across differentiated epithelial Caco-2 cell monolayers. TJ protein expression and cytoskeleton organization were investigated during and after exposure to penetramax or EGTA. Based on orthogonal methods, we show that penetramax acts by a mechanism that immediately and transiently widens the paracellular space, resulting in size selective permeant passage and with subsequent reconstitution of the epithelium. At the same time, the expression and organization of different TJ proteins are modulated reversibly. In contrast, the effect of EGTA on modulating the paracellular space is slower and TJ protein unspecific, and without clear permeant size selectivity. Overall, these data provide in-depth insights for understanding intestinal barrier dynamics of importance when evaluating new or existing excipients for oral delivery of biopharmaceuticals, such as peptide therapeutics.</p>
</abstract>
<kwd-group>
<kwd>penetramax</kwd>
<kwd>ethylene glycol tetraacetic acid (EGTA)</kwd>
<kwd>cell-penetrating peptide</kwd>
<kwd>tight junction</kwd>
<kwd>cytoskeleton</kwd>
<kwd>re-epithelization</kwd>
<kwd>permeation enhancer</kwd>
<kwd>oral drug delivery</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Oral Drug Delivery</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>The number of regulatory approvals for biopharmaceuticals are rising (<xref ref-type="bibr" rid="B28">Lau and Dunn, 2018</xref>; <xref ref-type="bibr" rid="B48">Walsh, 2018</xref>), driven by the increased discovery and application of novel peptide therapeutics for a variety of drug targets. This increases the need to develop competitive and patient-friendly dosage forms complementary to the current injectables (<xref ref-type="bibr" rid="B8">Brayden, 2020</xref>). Oral dosing is highly accepted among patients and while several formulations comprising permeation enhancers (PEs) as excipients have entered clinical trials to improve the oral bioavailability of peptide drugs, only two have been approved. These approved formulations utilize medium chain fatty acid (MCFA)-based PEs. Specifically, in Rybelsus<sup>&#xae;</sup> sodium salcaprozate is dosed together with the glucagon-like peptide-1 analog semaglutide for diabetes treatment, and in Mycapssa<sup>&#xae;</sup> sodium caprylate is co-administered with octreotide for acromegaly therapy (<xref ref-type="bibr" rid="B10">Buckley et al., 2018</xref>). Despite significant efforts, the achieved bioavailabilities are still low, partly attributed to the challenging environment in the gastrointestinal tract (<xref ref-type="bibr" rid="B4">Artursson and Lundquist, 2020</xref>; <xref ref-type="bibr" rid="B8">Brayden, 2020</xref>). E.g., while the intestinal epithelium regulates the absorption of nutrients and solutes, it represents a significant biological barrier to absorption of larger molecules such as therapeutic peptides (<xref ref-type="bibr" rid="B9">Brown et al., 2020</xref>; <xref ref-type="bibr" rid="B16">Drucker, 2020</xref>). Hence, it is crucial to address critical parameters when evaluating the effect of PEs on the intestinal epithelial barrier <italic>in vitro</italic>, facilitating their potential translation to clinical studies, as well as exploring additional PEs beyond MCFAs.</p>
<p>The intestinal epithelium consists of a monolayer of epithelial cells interconnected by cell-cell junctions, with tight junction (TJ) proteins being the primary determinants for permeation through the paracellular pathway (<xref ref-type="bibr" rid="B50">Weber, 2012</xref>; <xref ref-type="bibr" rid="B3">Apostolou et al., 2021</xref>). TJs are highly organized protein networks of transmembrane and cytoplasmic protein families (<xref ref-type="bibr" rid="B2">Anderson and Van Itallie, 2009</xref>; <xref ref-type="bibr" rid="B41">Shen, 2012</xref>; <xref ref-type="bibr" rid="B45">Van Itallie and Anderson, 2014</xref>). The former includes claudins, TJ-associated MARVEL proteins (e.g., occludin and tricellulin (tric)), and junctional adhesion molecules. Complementing these is, amongst others, the cytosolic scaffold protein family zonula occludens (ZO) that crosslinks most of the transmembrane TJ proteins to the underlying actin cytoskeleton (<xref ref-type="bibr" rid="B33">Monaco et al., 2021</xref>). This interconnectedness regulates the movement of ions and solutes through the paracellular space (<xref ref-type="bibr" rid="B20">Gonz&#xe1;lez-Mariscal et al., 2000</xref>; <xref ref-type="bibr" rid="B46">Van Itallie and Anderson, 2006</xref>; <xref ref-type="bibr" rid="B47">Van Itallie et al., 2009</xref>). Thus, an approach to improve transepithelial peptide drug permeation and hence the bioavailability of orally administered peptide drugs is to transiently modulate the TJ and cytoskeleton dynamics using PEs (<xref ref-type="bibr" rid="B24">Krug et al., 2013</xref>; <xref ref-type="bibr" rid="B7">Bocsik et al., 2016</xref>; <xref ref-type="bibr" rid="B27">Krug et al., 2017</xref>; <xref ref-type="bibr" rid="B34">Neuhaus et al., 2018</xref>). PEs can act transcellularly and/or paracellularly. Irrespective of the exact mechanism, a PE should be sufficiently efficient and safe to use implying that the effect should be rapid, selective, and reversible.</p>
<p>Examples of paracellularly acting PEs comprise the MCFA sodium caprate that interacts with the cell membrane leading to modulation of TJs and the paracellular space (<xref ref-type="bibr" rid="B24">Krug et al., 2013</xref>) and the small molecule and chelating agent, ethylene glycol tetraacetic acid (EGTA) known for its effect on epithelial barrier properties due to Ca<sup>2&#x2b;</sup> depletion (<xref ref-type="bibr" rid="B36">Raiman et al., 2003</xref>). EGTA is an analog of ethylenediaminetetraacetic acid (EDTA), which is included as one of more components in the POD&#x2122; technology that have been tested in patients for oral insulin delivery (<xref ref-type="bibr" rid="B43">Study Record, 2023</xref>), although it recently failed to meet clinical endpoints in a phase 3 study (<xref ref-type="bibr" rid="B43">Study Record, 2023</xref>). As EGTA is significantly more selective towards Ca<sup>2&#x2b;</sup> ions over Mg<sup>2&#x2b;</sup> ions, as compared to EDTA (<xref ref-type="bibr" rid="B11">Caldwell and Cuthbert, 1970</xref>), we selected EGTA as comparator in the present study. Previous studies found EDTA to effectively enhance permeation when applied in the one-digit mM range (<xref ref-type="bibr" rid="B35">Noach et al., 1993</xref>).</p>
<p>Here, we investigate the effects of penetramax, a membrane-interacting peptide-based enhancer, and analog of penetratin, a cell-penetrating peptide, which we and others previously reported to enhance peptide delivery <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B22">Kamei et al., 2013a</xref>; <xref ref-type="bibr" rid="B13">Diedrichsen et al., 2021</xref>). <italic>In vitro</italic>, effective concentrations of penetramax are in the two-digit &#xb5;M range (<xref ref-type="bibr" rid="B14">Diedrichsen et al., 2023</xref>). We compare the findings head-to-head to those observed with EGTA with the aim to analyze the underlying cellular mechanisms that regulate TJ and cytoskeleton dynamics for both enhancers. Thus, we aimed to address critical parameters for evaluating PE effects on epithelial barrier dynamics, permeant size selectivity, and epithelial barrier recovery.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Materials</title>
<p>Penetramax (KWFKIQMQIRRWKNKR, 2,247&#xa0;Da) was synthesized by Synpeptide (Shanghai, China) with a purity &#x3e;95%. EGTA ([-CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>2</sub>CO<sub>2</sub>H)<sub>2</sub>]<sub>2</sub>) with a purity &#x3e;97%, bovine serum albumin (BSA) with a purity &#x3e;98%, fluorescein isothiocyanate (FITC)-labeled dextrans 4 and 10 (FD4 and FD10, average Mw: 4,000&#xa0;g/mol and 10,000&#xa0;g/mol), phenazine methosulfate (PMS), polysorbate 20, Triton<sup>&#xae;</sup> X-100, EDTA, Trizma<sup>&#xae;</sup>, sucrose, Tergitol&#x2122; (NP-40) and skim milk powder for microbiology were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). 4-(2-hydroxyethyl)-1-piperazine-1- ethanesulfonic acid (HEPES) was purchased from PanReac AppliChem (Darmstadt, Germany). Hank&#x2019;s balanced salt solution containing 1&#xa0;mM Ca<sup>2&#x2b;</sup> and 0.9&#xa0;mM&#xa0;Mg<sup>2&#x2b;</sup> (HBSS), Dulbecco&#x2019;s phosphate-buffered saline (PBS, pH 7.2), Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM), penicillin/streptomycin, <sc>L</sc>-glutamine, non-essential amino acid solution (NEAA), and trypsin-EDTA, were purchased from Merck (Kenilworth, NJ, United States). ECL<sup>&#xae;</sup> immunoblotting detection reagents were obtained from GE Healthcare (Cardiff, United Kingdom). Phosphate-buffered saline, Tris-buffered saline (TBS), resin kit medium, 1,2 propylene oxide, and glutaraldehyde 25% (v/v) were from VWR (Radnor, PA, United States). 2-(N-morpholino) ethanesulfonic acid (MES) running buffer, 3-morpholinopropane-1-sulfonic acid sodium dodecyl sulfate (SDS) running buffer (MOPS), 16% (w/v) paraformaldehyde (PFA) aqueous solution methanol free (Alfa Aesar), 4,6-diamidino-2-phenylindole (DAPI), Alexa Fluor<sup>&#xae;</sup> 555 phalloidin, Pierce&#x2122; BCA protein kit, and Mount Medium Scientific&#x2122; Sadon&#x2122; Immu-Mount&#x2122; were purchased from Thermo Fisher Scientific (Waltham, MA, United States). Likewise, the antibodies rabbit anti-zonula occludens-1 (ZO-1) (&#x23;61-7300, RRID:AB_2533938), rabbit anti-occludin (&#x23;71-1500; RRID:AB_2533977), rabbit anti-tricellulin (tric) (&#x23;700191; RRID:AB_2532298), rabbit anti-claudin-1 (&#x23;717800; RRID:AB_2533997), rabbit anti-claudin-7 (&#x23;349100; RRID:AB_2533190), mouse anti-claudin-2 (&#x23;325600; RRID:AB_2533085), mouse anti-claudin-4 (&#x23;329400; RRID:AB_2533096), goat anti-mouse IgG (&#x23;31430; RRID:AB_228307), goat anti-rabbit (&#x23;31460; RRID:AB_22834), goat anti-rabbit IgG (H &#x2b; L) Trial Superclonal&#x2122; secondary antibody Alexa Fluor 488 (&#x23;A27034; RRID:AB_2536097) and goat anti-mouse IgG (H &#x2b; L) highly cross-adsorbed secondary antibody Alexa Fluor Plus 488 (&#x23;A32723; RRID:AB_2633275) were from Thermo Fisher Scientific. Rabbit anti-&#x3b2; actin antibody (&#x23;ab8227; RRID:AB_2305186) was purchased from Abcam (Burlingame, CA, United States). Abberior<sup>&#xae;</sup> STER RED NHS (&#x23;43354) and Abberior MOUNT<sup>&#xae;</sup> media were purchased by Abberior (G&#xf6;ttingen, Germany). Fetal bovine serum (FBS) was purchased from PAA laboratories (Br&#xf8;ndby, Denmark). 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) was obtained from Promega (Madison, WI, United States). Osmium tetroxide 4% (w/v) solution was from Polysciences Europe (Hirschberg an der Bergstrasse, Germany) and potassium ferricyanide from Fluka<sup>&#xae;</sup> Analytical (Buchs, Switzerland). Ultrapure water was obtained from a PURELAB flex 4 system (ELGA LabWater, High Wycombe, United Kingdom).</p>
</sec>
<sec id="s2-2">
<title>2.2 Cell culture</title>
<p>The human colorectal adenocarcinoma cell line Caco-2 (American Type Culture Collection (ATCC) &#x23;HTB-37<sup>;</sup> RRID:CVCL_0025, Manassas, VA, United States) was maintained in T175 cm<sup>2</sup> flasks (Merck) in high-glucose DMEM supplemented with 10% (v/v) FBS, 0.1&#xa0;mM NEAA, 2&#xa0;mM&#xa0;<sc>L</sc>-glutamine, 90 IU/mL penicillin, and 90&#xa0;&#x3bc;g/mL streptomycin, in a humidified atmosphere (5% CO<sub>2</sub>, 95% O<sub>2</sub>, 37&#xb0;C). The cell culture medium was changed every second day. The cells were passaged using trypsin-EDTA at 80%-85% confluency once a week. For experimental use, the Caco-2 cells were seeded (1 &#xd7; 10<sup>5</sup> cells/insert) on polycarbonate Corning Transwell<sup>&#xae;</sup> filter inserts (model 3140, 0.4&#xa0;&#xb5;m pore size, 1.12&#xa0;cm<sup>2</sup>, Corning, NY, United States) and cultured in a humidified atmosphere (5% CO<sub>2</sub>, 95% O<sub>2</sub>, 37&#xb0;C) for 21&#xa0;days in cell culture medium with medium change every second day and the day before an experiment. Passage 3&#x2013;11 were used for experiments. The initial transepithelial electrical resistance (TEER) values for Caco-2 cells grown on filter inserts included in the studies ranged from 226 to 400&#xa0;&#x3a9; &#xd7; cm<sup>2</sup> with similar TEER values within each passage and the main variation observed between passages.</p>
</sec>
<sec id="s2-3">
<title>2.3 Test samples</title>
<p>Stock solutions (1&#xa0;mM) of penetramax were prepared in ultrapure water based on weighed powder including the presence of trifluoroacetic acid as counterion. The desired test concentrations of 25, 55, 75, and 95&#xa0;&#xb5;M penetramax were obtained upon appropriate dilution in 10&#xa0;mM HEPES-HBSS (Ca<sup>2&#x2b;</sup>/Mg<sup>2&#x2b;</sup>) pH 7.4 (referred to as hHBSS). Stock solutions of EGTA (100&#xa0;mM, pH 7.8) were prepared in ultrapure water and further diluted in hHBSS prior use to achieve the desired final concentrations of 1, 3, 5, and 7&#xa0;mM EGTA.</p>
</sec>
<sec id="s2-4">
<title>2.4 Transepithelial electrical resistance (TEER)</title>
<sec id="s2-4-1">
<title>2.4.1 End-point TEER measurements</title>
<p>The Caco-2 cell monolayers were washed twice with 37&#xb0;C hHBSS or hHBSS supplemented with 0.05% (w/v) BSA on both the apical and basolateral sides, respectively. The monolayers were equilibrated to room temperature (RT) for 20&#xa0;min in the last washing volume prior to TEER measurements using an ENDOHM 12-G cup connected to an EVOM volt ohmmeter (World Precision Instruments, Sarasota, FL, United States). PE concentrations in the ranges 1&#x2013;10&#xa0;mM for EGTA and 10&#x2013;100&#xa0;&#xb5;M for penetramax (data not shown) were screened for their effect on TEER after 3&#xa0;h incubation as described below, and four concentrations were selected for each of the PEs. The buffer was replaced with 0.35&#xa0;mL of test sample consisting of 25, 55, 75, or 95&#xa0;&#xb5;M penetramax or 1, 3, 5, or 7&#xa0;mM EGTA in hHBSS in the apical compartment and with 1&#xa0;mL hHBSS supplemented with 0.05% (w/v) BSA in the basolateral compartment. The monolayers were transferred to a 37&#xb0;C shaking table with orbital shaking (50&#xa0;rpm) (Thermo MaxQ 2000, Thermo Fischer Scientific, West Palm Beach, FL, United States with custom-made temperature isolation). After 3&#xa0;h of exposure, the cells were left at RT to equilibrate for 20&#xa0;min prior to TEER measurements. After TEER measurements, the Caco-2 cell monolayers were washed twice with 37&#xb0;C hHBSS or hHBSS supplemented with 0.05% (w/v) BSA on the apical and basolateral sides, respectively, and kept in cell culture medium for recovery for additional 18&#xa0;h in an incubator (5% CO<sub>2</sub>, 95% O<sub>2</sub>, 37&#xb0;C). Subsequently, and after 20&#xa0;min equilibration to RT, the monolayers were subjected to TEER measurements. The epithelial integrity was calculated according to Eq. <xref ref-type="disp-formula" rid="e1">1</xref>.<disp-formula id="e1">
<mml:math id="m1">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mo>,</mml:mo>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mo>,</mml:mo>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:math>
<label>(1)</label>
</disp-formula>
</p>
</sec>
<sec id="s2-4-2">
<title>2.4.2 Real time TEER measurements</title>
<p>To test the effect of 25, 55, 75, and 95&#xa0;&#xb5;M penetramax and 1, 3, 5, and 7&#xa0;mM EGTA on the integrity of Caco-2 cell monolayers in real time, a CellZscope (nanoAnalytics, M&#xfc;nster, Germany) was used to record TEER every 20&#xa0;min. 20&#xa0;days post-seeding, Caco-2 cells grown on filter supports were transferred to CellZscope chambers with 1&#xa0;mL and 1.5&#xa0;mL cell culture medium in the apical and basolateral compartments, respectively. The Caco-2 cell monolayers were placed in an incubator (37&#xb0;C and 5% CO<sub>2</sub> humidified air) and left to equilibrate overnight (ON). Then, the cell monolayers were washed twice with hHBSS (1&#xa0;mL) and hHBSS supplemented with 0.05% (w/v) BSA (1.5&#xa0;mL) on the apical and basal sides, respectively, and left to equilibrate for 1&#xa0;h (37&#xb0;C and 5% CO<sub>2</sub> humidified air). When testing the effect of different penetramax and EGTA concentrations, 20&#x2013;45&#xa0;&#xb5;L of the excipient stock was spiked into the apical hHBSS buffer (maintaining a total volume of 800&#xa0;&#xb5;L in the apical compartment) followed by 3&#xa0;h exposure with orbital shaking (50&#xa0;rpm) at 37&#xb0;C. The test samples were gently removed, and the cell monolayers were washed twice with hHBSS and hHBSS supplemented with 0.05% (w/v) BSA on the apical and basolateral sides, respectively, and placed in cell culture medium for subsequent TEER measurements. Effects are presented as percent of TEER upon equilibration at 37&#xb0;C normalized to that of cell monolayers in buffer with t<sub>0</sub> being the time of excipient addition and recovery initiation (Eq. <xref ref-type="disp-formula" rid="e2">2</xref>). TEER values are always measured at 37&#xb0;C and compared at every recorded cycle occurring every 20&#xa0;min. Eq. <xref ref-type="disp-formula" rid="e2">2</xref> thus describes a continuous measurement of TEER changes over time (during exposure and recovery) compared to the baseline after equilibration.<disp-formula id="e2">
<mml:math id="m2">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">x</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:msub>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">x</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext>&#x2009;&#x2009;</mml:mtext>
<mml:msub>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:math>
<label>(2)</label>
</disp-formula>
</p>
</sec>
</sec>
<sec id="s2-5">
<title>2.5 Metabolic activity</title>
<p>The metabolic activity of the 21-day post-seeding differentiated Caco-2 cell monolayers was evaluated after 3&#xa0;h incubation with buffer, with 25, 55, 75, or 95&#xa0;&#xb5;M penetramax, or with 1, 3, 5, or 7&#xa0;mM EGTA as well as upon 21&#xa0;h recovery using the MTS-PMS assay. Following penetramax or EGTA exposure, the monolayers were washed twice with 37&#xb0;C hHBSS or hHBSS supplemented with 0.05% (w/v) BSA on the apical or basolateral side, respectively. The buffer was replaced with 0.35&#xa0;mL of MTS-PMS (240&#xa0;&#x3bc;g/mL MTS and 2.4&#xa0;&#x3bc;g/mL PMS) in hHBSS in the apical compartment and 1&#xa0;mL hHBSS supplemented with 0.5% (w/v) BSA in the basolateral compartment. The inserts were transferred to a 37&#xb0;C shaking table (Thermo Fisher Scientific with temperature isolation) applying orbital shaking (50&#xa0;rpm) for 60-90&#xa0;min 2 &#xd7; 100&#xa0;&#xb5;L samples from the apical compartment were transferred to a clear-bottom 96-well plate (Greiner, Pleidelsheim, Germany), and the absorbance was measured at 490&#xa0;nm using a FLUOstar OPTIMA plate reader (BMG Labtech, Ortenberg, Germany). The relative metabolic activity was calculated using Eq. <xref ref-type="disp-formula" rid="e3">3</xref>:<disp-formula id="e3">
<mml:math id="m3">
<mml:mrow>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">v</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">v</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">y</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">A</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi mathvariant="normal">C</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">B</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi mathvariant="normal">C</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:math>
<label>(3)</label>
</disp-formula>where A is the absorbance of samples taken from the apical side of Caco-2 cell monolayers exposed to penetramax or EGTA, B is the absorbance of samples taken from the apical side of Caco-2 cell monolayers in hHBSS, and C is the absorbance of MTS-PMS reagent included as background control, instead of cells exposed to e.g., 0.2% (w/v) sodium dodecyl sulfate as a positive control since SDS lyses and/or fully detaches the cells from the filter insert leaving only buffer with the MTS-PMS reagent as the C sample.</p>
</sec>
<sec id="s2-6">
<title>2.6 FITC-labeled dextran (FD) permeation</title>
<p>The Caco-2 cell monolayers were washed and the TEER measured as described for the end-point TEER measurements. The permeation study was done in the same wells as used for the TEER measurement. Then, the buffer was replaced with 0.37&#xa0;mL of 25, 55, 75, or 95&#xa0;&#xb5;M penetramax or 1, 3, 5, or 7&#xa0;mM EGTA together with 1&#xa0;mg/mL FD4 or FD10 kDa in hHBSS in the apical compartment. 1&#xa0;mL hHBSS supplemented with 0.05% (w/v) BSA was used in the basolateral compartment. The inserts were transferred to a 37&#xb0;C shaking table (Thermo Fischer Scientific, with temperature isolation) employing orbital shaking (50&#xa0;rpm) for 3&#xa0;h. 20&#xa0;&#x3bc;L donor samples were withdrawn from the apical compartment at time points 0 and 180&#xa0;min and 100&#xa0;&#x3bc;L samples were withdrawn from the basolateral compartment at time points 30, 60, 90, 120, 150, and 180&#xa0;min and kept protected from light in a black clear-bottom 96-well plate (Nunc, Roskilde, Denmark) until analysis immediately after termination of the experiment. The 100&#xa0;&#xb5;L sampling volumes were replaced with hHBSS supplemented with 0.05% (w/v) BSA. FD permeation was evaluated using a SPECTROstar fluorescence plate reader (BMG LABTECH, Offenberg, Germany) with excitation/emission set to 480/520&#xa0;nm.</p>
<p>The apparent permeability coefficient, P<sub>app</sub>, was calculated according to Eq. <xref ref-type="disp-formula" rid="e4">4</xref>:<disp-formula id="e4">
<mml:math id="m4">
<mml:mrow>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>p</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>&#x3d;</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">Q</mml:mi>
<mml:mo>/</mml:mo>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi mathvariant="normal">A</mml:mi>
<mml:mo>&#xd7;</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<label>(4)</label>
</disp-formula>where P<sub>app</sub> (cm/s) is the apparent permeability, dQ/dt (&#xb5;g/s) is the steady-state flux, A is the area of the filter insert (1.12&#xa0;cm<sup>2</sup>), and C<sub>0</sub> (&#xb5;g/mL) is the initial donor sample concentration. The P<sub>app</sub> presented was calculated for t &#x3d; 30-90&#xa0;min.</p>
</sec>
<sec id="s2-7">
<title>2.7 Tight junction and cytoskeleton visualization using confocal laser scanning microscopy (CLSM) and stimulation emission depletion (STED) microscopy</title>
<p>Changes in TJ localization and morphology of Caco-2 cell monolayers were analyzed after 3&#xa0;h incubation with 25, 55, 75, or 95&#xa0;&#xb5;M penetramax or 1, 3, 5, or 7&#xa0;mM EGTA, and after 21&#xa0;h subsequent recovery in growth medium. The Caco-2 cell monolayers were washed twice with hHBSS and hHBSS supplemented with 0.05% (w/v) BSA apically and basolaterally, respectively. The cell monolayers were fixed with 3.7% (v/v) paraformaldehyde in PBS for 15&#xa0;min at RT. After two washing steps with PBS, the monolayers were permeabilized with 0.2% (v/v) Triton&#x2122; X-100 in PBS for 15&#xa0;min. Next, they were blocked with 4% (w/v) BSA in PBS (blocking buffer) for 40&#xa0;min and separated from the plastic inserts before incubation with the primary antibodies (directed against claudin-1 (1:200), &#x2212;2 (1:180), &#x2212;4 (1:180), &#x2212;7 (1:180), ZO-1 (1:150), occludin (1:200), and tric (1:180)) and phalloidin (1:100), to stain the cytoskeleton filamentous actin (F-actin), in blocking buffer at 4&#xb0;C ON with horizontal shaking (100&#xa0;rpm). The cell monolayers were washed once with PBS (RT) and incubated for 45&#xa0;min in blocking buffer at RT, and then incubated with secondary antibody (1:200) diluted in blocking buffer for 1&#xa0;h at RT with horizontal shaking (100&#xa0;rpm). The nuclei were stained with DAPI (1:10000) for 15&#xa0;min. Monolayers then were washed twice with PBS before being mounted on microscope slides using Immuno Mount<sup>&#xae;</sup> for CLSM and Aberrior Mount<sup>&#xae;</sup> for STED microscopy using 1.5H thickness coverslips. Images were captured using a Zeiss LSM710 confocal microscope (Carl Zeiss, Jena, Germany) equipped with a 405&#xa0;nm diode laser for DAPI, 488&#xa0;nm argon laser for Alexa Fluor<sup>&#xae;</sup> 488, and a 561&#xa0;nm diode-pumped solid-state laser for phalloidin using a PMT detector for capturing the DAPI signal and a GaAsP detector for the Alexa Fluor<sup>&#xae;</sup> 488 and Alexa Fluor<sup>&#xae;</sup> 555 signals, using Nyquist sampling. For STED imaging, a STEDYCON (Abberior Instruments, G&#xf6;ttingen, Germany) system confocal microscope (Carl Zeiss, Jena, Germany) equipped with 561&#xa0;nm and 640&#xa0;nm pulsed excitation lasers and a 775&#xa0;nm pulsed depletion laser using 20&#xa0;nm pixels. For image acquisition, a Plan-Apochromat 63&#xd7;/1.4 N.A. oil immersion objective (confocal microscopy) and a &#xd7;100/1.46 N.A. oil immersion objective (STED microscopy) was used for scanning in the lateral and axial directions. When necessary, the intensity of the images was adjusted for brightness and contrast and the images were displayed as maximum projections using the ImageJ<sup>&#xae;</sup> software program (<xref ref-type="bibr" rid="B40">Schneider et al., 2012</xref>). To prepare the microscopy figures, the open-source plug-in ScientiFig for ImageJ<sup>&#xae;</sup> was used (<xref ref-type="bibr" rid="B1">Aigouy and Mirouse, 2013</xref>). Deconvolution of STED images was performed with Huygens software.</p>
</sec>
<sec id="s2-8">
<title>2.8 Ultrastructural analysis using transmission electron microscopy (TEM)</title>
<p>The ultrastructure of the Caco-2 cell monolayers was analyzed after 3&#xa0;h incubation with 25, 55, 75, or 95&#xa0;&#xb5;M penetramax or 7&#xa0;mM EGTA, and after 21&#xa0;h subsequent recovery in growth medium, using TEM. The monolayers were washed twice with PBS and subsequently fixated with 2% (v/v) glutaraldehyde in 0.05&#xa0;M in PBS at RT (for at least 24&#xa0;h), prior to washing twice with 0.12&#xa0;M cacodylate for 20&#xa0;min. The cells were subjected to post-fixation in 1% (w/v) osmium tetroxide, 0.05&#xa0;M potassium ferricyanide, and 0.12&#xa0;M cacodylate for 1&#xa0;h at RT and dehydrated stepwise in a graded ethanol series (70%, 96%, and absolute ethanol) thrice for 15&#xa0;min for each step. The monolayers were infiltrated in propylene oxide and subsequently in 1/3, 1/1, and 3/1 proportions of Epon (TAAB, T031)/polypropylene oxide gradients for 40&#xa0;min per gradient and finally in pure Epon resin for 2&#xa0;h under gentle rotation. Resin polymerization was performed ON at 60&#xb0;C. Ultra-thin sections, approximately 60&#xa0;nm thick, were cut with an Ultracut 7 microtome (Leica, Vienna, Austria) and collected on copper grids with Formvar supporting membranes, stained with uranyl acetate and lead citrate, and subsequently examined using a Philips CM 100 Transmission EM (Philips, Eindhoven, Netherlands), operated at an accelerating voltage of 80&#xa0;kV. Digital images were recorded with an OSIS Veleta digital slow scan 2k &#xd7; 2k CCD camera and the ITEM software package.</p>
</sec>
<sec id="s2-9">
<title>2.9 Protein expression analysis using immunoblotting</title>
<p>Changes in TJ protein expression was evaluated after 3&#xa0;h exposure to 25, 55, 75, or 95&#xa0;&#xb5;M penetramax or 1, 3, 5, or 7&#xa0;mM EGTA, and after 21&#xa0;h recovery in growth medium, using immunoblotting. The Caco-2 cell monolayers were washed twice with ice-cold hHBSS, and the cells were lysed with 2% (v/v) NP-40 cell lysis buffer (10&#xa0;mM Tris-HCl, pH 7.4, 0.25&#xa0;M sucrose, 1&#xa0;mM EGTA, 1&#xa0;mM EDTA, 2% (v/v) NP-40) supplemented with protease inhibitor cocktail (Complete Mini, Roche Diagnostics, Basel, Switzerland) for 30&#xa0;min on ice. The cell lysates were subjected to centrifugation for 15&#xa0;min at 1500&#xa0;g and 0&#xb0;C (Eppendorf<sup>&#xae;</sup> microcentrifuge, Eppendorf Nordic, H&#xf8;rsholm, Denmark). The supernatants were stored at &#x2212;20&#xb0;C or &#x2212;80&#xb0;C until use. The total protein in the lysates was quantified using the BCA protein quantification kit (Pierce&#x2122;, Thermo Scientific) as directed by the manufacturer. 12.5-20&#xa0;&#xb5;g protein were loaded onto NuPAGE&#x2122; 4%-12% Bis-Tris gels (Novex Life Technologies, Invitrogen, Thermo Scientific) for separation using a miniXCell<sup>&#xae;</sup> device (Novex Life Technologies). The protein bands were electro-transferred onto a polyvinylidene difluoride membrane using Trans-Blot<sup>&#xae;</sup> Turbo&#x2122; Mini PVDF Transfer Packs (Bio-Rad, Hercules, CA, United States) and the Trans-Blot Turbo Transfer Starter System (Bio-Rad). The membrane was blocked with 5% (v/v) skim milk in TBS with 0.1% (v/v) polysorbate 20 for 1&#xa0;h before incubation with primary antibodies [anti-claudin-1, anti-claudin-2, anti-claudin-4, anti-claudin-7, anti-tric (all 1:1000), anti-ZO-1 and anti-occludin (1:1500)] at 4&#xb0;C ON. The membrane was washed thrice with TBS with 0.1% (v/v) polysorbate 20 prior incubation with horseradish peroxidase-conjugated secondary antibody (1:4000 for monoclonal anti-mouse and 1:7000 for polyclonal anti-rabbit apart from occludin, for which the dilution factor was 1:8500) for 1&#xa0;h and washed five times with 0.1% (v/v) polysorbate 20 in TBS. The membranes were visualized using an ECL<sup>&#xae;</sup> Prime Western blotting System in a Fluorochem Q imaging system (Alpha Innotech, Santa Clara, CA, United States). Equal protein loading was assessed by membrane re-probing with anti-&#x3b2; actin (1:5000) antibody as described above. The only difference was that the incubation for the primary antibody was 1 h, and the dilution of the secondary antibody was 1:11000. The densitometry analysis was performed with Fluorochem Q software for semi-quantifying the bands corresponding to the TJ protein under investigation and normalized against bands for anti-&#x3b2; actin as a loading control.</p>
</sec>
<sec id="s2-10">
<title>2.10 Data and statistical analysis</title>
<p>Data analysis was performed with Microsoft Excel 2010 software (RRID:SCR_016137; Microsoft, Houston, TX, United States) and GraphPad Prism 7 (RRID:SCR_002798; GraphPad Software, San Diego, CA, United States). Data are presented as mean with standard error of mean (SEM) apart from TJ protein expression from immunoblots for which standard deviation (SD) were used. &#x201c;n&#x201d; represents the number of technical replicates within each passage of cells and &#x201c;N&#x201d; represents the number of independent biological experiments. Statistical analysis was performed by GraphPad Prism 7 using one-way analysis of variance (ANOVA) followed by Dunnett&#x2019;s T3 multiple comparison for data with unequal SDs.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Penetramax and EGTA decrease epithelial integrity without corresponding effects on cell metabolic activity</title>
<p>We used the TEER of the differentiated Caco-2 cell monolayers to provide insight into the effects of penetramax and EGTA on the epithelial barrier integrity. A screening of various concentrations was performed, and subsequent investigations focused on excipient concentrations that after 3&#xa0;h exposure resulted in approximately 95%, 80%, 60%, and 40% of the initial TEER. Penetramax decreased the TEER to 96%, 75%, 59%, and 43% upon exposure to 25, 55, 75, and 95&#xa0;&#xb5;M penetramax, respectively (<xref ref-type="fig" rid="F1">Figure 1A</xref>). In comparison, the TEER decreased to 96%, 84%, 58%, and 34% upon exposure to 1, 3, 5, and 7&#xa0;mM EGTA, respectively (<xref ref-type="fig" rid="F1">Figure 1B</xref>). As an indicator of the effect of penetramax and EGTA on cellular viability, the metabolic (dehydrogenase) activity was assessed after 3&#xa0;h exposure. The metabolic activity was not reduced to the same extent as the TEER by penetramax exposure, and only resulted in a significant decrease by 28% after exposure to the highest penetramax concentration (<xref ref-type="fig" rid="F1">Figure 1C</xref>). In contrast, exposure to EGTA resulted in a concentration-dependent stimulation of the metabolic activity corresponding to increases of 23%, 32%, and 38% for 3, 5, and 7&#xa0;mM EGTA, respectively, when compared to the buffer exposed cells (<xref ref-type="fig" rid="F1">Figure 1D</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Comparable TEER reduction between 25, 55, 75, 95&#xa0;&#xb5;M penetramax and 1, 3, 5, 7&#xa0;mM EGTA after 3&#xa0;h exposure. Effects on the integrity and metabolic activity were transient upon recovery. End-point TEER measurements of Caco-2 cell monolayers exposed to <bold>(A)</bold> penetramax and <bold>(B)</bold> EGTA for 3&#xa0;h and subsequent recovery in cell culture medium for 21&#xa0;h. N &#x3d; 3&#x2013;4, <italic>n</italic> &#x3d; 3&#x2013;6. Metabolic activity in Caco-2 cell monolayers exposed to <bold>(C)</bold> penetramax and <bold>(D)</bold> EGTA for 3&#xa0;h and after subsequent recovery in cell culture medium for 21&#xa0;h of exposure. N &#x3d; 3&#x2013;5, <italic>n</italic> &#x3d; 2&#x2013;6 <bold>(A&#x2013;D)</bold> Horizontal lines represent baseline values. Results are shown as mean &#xb1; SEM in comparison to buffer. &#x2a;) <italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fddev-03-1221628-g001.tif"/>
</fig>
<p>After 3&#xa0;h exposure to penetramax or EGTA, the cell monolayers were washed and subjected to 21&#xa0;h recovery in cell culture medium. Overall, both the integrity and the cellular metabolic activity were reestablished (<xref ref-type="fig" rid="F1">Figures 1A&#x2013;D</xref>), yet the cell monolayers exposed to 75 and 95&#xa0;&#xb5;M penetramax displayed slightly increased TEER values by 23% and 27%, respectively. This was also the case for the metabolic activity of cell monolayers exposed to 7&#xa0;mM EGTA (19%).</p>
<p>These results indicate that penetramax and EGTA exert similar and reversible effects on epithelial integrity. However, upon recovery for 21 h, the epithelial integrity was at baseline values only for EGTA, while increased for penetramax. The metabolic activity was at baseline for penetramax after 21&#xa0;h recovery.</p>
</sec>
<sec id="s3-2">
<title>3.2 Penetramax and EGTA induce contraction of the perijunctional actomyosin ring, but display different morphological effects and degrees of cytoskeletal restoration</title>
<p>To investigate cytoskeletal changes underlying the effects induced by penetramax and EGTA on the epithelial integrity and metabolic activity, penetramax and EGTA exposed cell monolayers were stained with phalloidin. This was done immediately after exposure and following recovery to investigate the changes in filamentous (F)-actin. Buffer (<xref ref-type="fig" rid="F2">Figure 2</xref>) and the lowest concentration of penetramax (25&#xa0;&#xb5;M) and EGTA (1&#xa0;mM) exposed cells (<xref ref-type="sec" rid="s11">Supplementary Figure S1B</xref>) revealed the characteristic apical tight perijunctional actomyosin ring. In contrast, exposure to the high concentrations of penetramax (75 and 95&#xa0;&#xb5;M) and EGTA (5 and 7&#xa0;mM) induced F-actin reorganization and contraction (<xref ref-type="fig" rid="F2">Figures 2A, B</xref>; <xref ref-type="sec" rid="s11">Supplementary Figures S1B&#x2013;F</xref>) as well as a rounded cellular morphology (<xref ref-type="sec" rid="s11">Supplementary Figures S1B, C</xref>). At intermediate concentrations (55&#xa0;&#xb5;M penetramax and 3&#xa0;mM EGTA), the cellular morphology was also altered, however, not to the same extent (<xref ref-type="fig" rid="F2">Figures 2A, B</xref>). After exposure to 55&#xa0;&#xb5;M penetramax (<xref ref-type="fig" rid="F2">Figure 2A</xref>), the apical membranes with the characteristic brush border structure of the microvilli appeared stretched, while with 3&#xa0;mM EGTA (<xref ref-type="fig" rid="F2">Figure 2B</xref>) the brush border appeared disassembled. Despite the cytoskeletal re-organization, cell monolayers showed signs of reconstitution with some phenotypic changes after the recovery period. A smaller cell height-to-area ratio was observed compared to the buffer exposed cells, corresponding to stretched apical membranes and a seemingly reduced cell volume for the intermediate penetramax concentration (<xref ref-type="fig" rid="F2">Figure 2A</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S1C</xref>), while for the highest penetramax concentration, the formation of stress fibers on the basal side of the Caco-2 cell monolayers was observed (<xref ref-type="sec" rid="s11">Supplementary Figures S1C, S1E</xref>). A similar cytoskeletal reorganization was observed after exposure to EGTA, yet some cells appeared to be devoid of actin filaments (<xref ref-type="fig" rid="F2">Figure 2B</xref> arrows).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Penetramax and EGTA contract the actin cytoskeleton (F-actin) after 3&#xa0;h of exposure with paracellular space widening, cytoskeletal reconstitution, and tight junction sealing after subsequent recovery. Representative confocal images of rhodamine-conjugated phalloidin for staining the F-actin. Images presented as maximum intensity projections of Caco-2 cell monolayers exposed to <bold>(A)</bold> penetramax (zoom, selected from <xref ref-type="sec" rid="s11">Supplementary Figure S1C</xref>) and <bold>(B)</bold> EGTA (zoom, selected from <xref ref-type="sec" rid="s11">Supplementary Figure S1D</xref>) for 3&#xa0;h (top row, 3 planes) and after subsequent recovery in cell culture medium for 21&#xa0;h (bottom row, three planes). Nuclei stained in blue. N &#x3d; 2 and <italic>n</italic> &#x3d; 1, except for penetramax 3&#xa0;h exposure where N &#x3d; 3, <italic>n</italic> &#x3d; 1. Scale bar 10&#xa0;&#xb5;m <bold>(C)</bold> Representative transmission electron micrographs of Caco-2 cell epithelium exposed to 95&#xa0;&#xb5;M penetramax and 7&#xa0;mM EGTA for 3&#xa0;h (top row) and after subsequent recovery in cell culture medium for 21&#xa0;h (bottom row). M: Microvilli, TJs: Tight junctions, D: Desmosomes. Scale bar 500&#xa0;nm for 3 h and 1&#xa0;&#xb5;m for recovery. N &#x3d; 2, <italic>n</italic> &#x3d; 1. Images are zoom-in of selected images in <xref ref-type="sec" rid="s11">Supplementary Figure S1C</xref> <bold>(A, B)</bold> and <xref ref-type="sec" rid="s11">Supplementary Figure S2</xref> <bold>(C)</bold>.</p>
</caption>
<graphic xlink:href="fddev-03-1221628-g002.tif"/>
</fig>
<p>Also, Caco-2 cell monolayers were subjected to TEM imaging to examine potential effects of the excipients on the monolayer ultrastructure. Upon exposure to the high concentration of penetramax (95&#xa0;&#xb5;M), a widening of the TJs and desmosomes was observed along with the formation of cell multilayers (<xref ref-type="fig" rid="F2">Figure 2C</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>), whereas exposure to the highest concentration of EGTA (7&#xa0;mM) resulted in a complete opening of the paracellular space and de-localization of TJs from the lateral to the basal compartment (<xref ref-type="sec" rid="s11">Supplementary Figure S2A</xref> bottom row). After recovery from penetramax exposure, the epithelium morphology reverted to a monolayer, though seemingly smaller in cell volume compared to the volume of buffer exposed cell monolayers (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref> bottom row). Notably, TJs were present at the apical surface and sealed the paracellular space (<xref ref-type="fig" rid="F2">Figure 2C</xref>, bottom row). Intriguingly, although cytoskeletal reconstitution was observed after exposure to 7&#xa0;mM EGTA, multilayers were formed (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>) and TJs were largely absent.</p>
<p>Collectively, these data show that despite both excipients seemingly contract the actomyosin perijunctional ring, penetramax induced widening of the paracellular space while EGTA fully opened it.</p>
</sec>
<sec id="s3-3">
<title>3.3 Penetramax and EGTA both affect the dynamics of the cell monolayer integrity, but only penetramax facilitates permeant size selectivity</title>
<p>Next, epithelial integrity was monitored in real time to understand the cellular mechanisms involved in the observed cytoskeletal reorganization and reconstitution resulting from exposure to penetramax or EGTA. TEER was recorded every 20&#xa0;min by impedance spectroscopy for 24&#xa0;h following the exposure to penetramax (<xref ref-type="fig" rid="F3">Figure 3A</xref>) or EGTA (<xref ref-type="fig" rid="F3">Figure 3B</xref>). For penetramax, a fast-acting mechanism was observed, with a significant, immediate, and concentration-dependent, yet transient, decrease in TEER. Reversibility was gradual and continuous during the exposure to penetramax. Consistent with what was observed in the endpoint measurements (<xref ref-type="fig" rid="F1">Figure 1A</xref>), the increase in TEER continued during recovery in a concentration-dependent manner, peaking at values 27%&#x2013;59% higher than that recorded in the buffer exposed cell monolayers (<xref ref-type="fig" rid="F3">Figure 3A</xref>). In contrast, EGTA exposure resulted in a slower, concentration-dependent decrease in TEER, followed by a plateau phase; except for highest concentration (7&#xa0;mM), where the TEER continued to decrease to a maximum decrease of 66% after 3&#xa0;h EGTA exposure. Upon replacing the EGTA samples with cell culture medium, the Caco-2 cell monolayers regained their baseline TEER within 1&#x2013;2&#xa0;h (<xref ref-type="fig" rid="F3">Figure 3B</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Immediate and transient effect of penetramax during exposure in contrast to the slower and gradual effect of EGTA on epithelial integrity and their corresponding permeability effects. Real time TEER measurements for cell monolayers exposed to <bold>(A)</bold> penetramax and <bold>(B)</bold> EGTA. Permeation of <bold>(C)</bold> FD4 and <bold>(D)</bold> FD10 across Caco-2 cell monolayers exposed to penetramax and <bold>(E)</bold> calculated P<sub>app</sub> values from steady state flux between 30 and 90&#xa0;min. N &#x3d; 2&#x2013;3, <italic>n</italic> &#x3d; 3&#x2013;6. Permeation of <bold>(F)</bold> FD4 and <bold>(G)</bold> FD10 across Caco-2 cell monolayers exposed to EGTA and <bold>(H)</bold> calculated P<sub>app</sub> values from steady state flux between 30- and 90-min. N &#x3d; 2-3, <italic>n</italic> &#x3d; 2-4. All experiments were done in triplicates (N &#x3d; 3), yet some of the first time point samples in the buffer and low permeation enhancer samples displayed no signal over the limit of detection leading to exclusion of those samples, and thus reduced N and n (for details, see <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). Results are shown as mean &#xb1; SEM. &#x2a;) <italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fddev-03-1221628-g003.tif"/>
</fig>
<p>To determine the impact of penetramax and EGTA on size-selectivity of epithelial permeability, the permeation of FD4 and FD10 across Caco-2 cell monolayers was assessed (<xref ref-type="fig" rid="F3">Figures 3C&#x2013;H</xref>). During exposure to penetramax concentrations higher than 25&#xa0;&#x3bc;M, the permeation of both FD4 and FD10 increased in a concentration-dependent manner, but with FD4 permeating the barrier to a higher degree than FD10, thus indicating size-selectivity in this molecular size range (<xref ref-type="fig" rid="F3">Figures 3C&#x2013;E</xref>). These permeation profiles revealed a non-linear relationship between accumulated mass and time with a decrease in flux over time. In contrast, the permeation profiles of FD4 and FD10 during epithelial exposure to EGTA showed steady-state permeation kinetics, except for the 7&#xa0;mM concentration, for which the permeation rate tended to increase at the later time points and for which the variation in flux also increased (<xref ref-type="fig" rid="F3">Figures 3F, G</xref>). Also, in contrast to that of penetramax, the effect of EGTA did not demonstrate clear size-selectivity, as the calculated P<sub>app</sub> values were similar for FD4 and FD10 applied together with EGTA (<xref ref-type="fig" rid="F3">Figure 3H</xref>).</p>
<p>To gain further insight into the fast-acting mechanism of penetramax, F-actin and occludin were stained in Caco-2 cell monolayers exposed to 75&#xa0;&#xb5;M penetramax for just 5 and 45&#xa0;min (<xref ref-type="fig" rid="F4">Figure 4</xref>). During that period, penetramax exerted its most pronounced and immediate effect on the TEER (<xref ref-type="fig" rid="F3">Figure 3A</xref>). Upon exposure to penetramax for 5&#xa0;min (<xref ref-type="fig" rid="F4">Figure 4</xref>), microvilli appearance changed in a small population of cells, and cytoskeletal contraction was observed after 45&#xa0;min. After exposure to penetramax for 5&#xa0;min, the characteristic punctate localization of occludin in tricellular TJs (tTJs), the meeting point of three epithelial cells, changed to a bicellular TJ (bTJ) pattern (<xref ref-type="fig" rid="F4">Figure 4</xref>, arrow) and after 45&#xa0;min, occludin internalized into the cytosol. STED microscopy analysis revealed that bTJs widened after only 5&#xa0;min exposure to penetramax, along with internalization of occludin, followed by widening of also the tTJs after 45&#xa0;min.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Penetramax at high concentration (75&#xa0;&#xb5;M) contracts the F-actin cytoskeleton and widens bicellular TJs (bTJs) and tricellular TJs (tTJs) after 45&#xa0;min exposure (top row). Internalization of occludin (mid and bottom rows, white arrow) and widening of bTJs (yellow arrows) after 5 min, followed by widening of tTJs after 45&#xa0;min (white arrows) occurs after exposure to 75&#xa0;&#xb5;M penetramax. Representative confocal and STED images of Caco-2 cell monolayers stained for F-actin (confocal) and occludin (confocal and STED) after exposure to buffer for 5&#xa0;min, 75&#xa0;&#xb5;M penetramax for 5 min, and for 45&#xa0;min (F-actin in red, occludin in green for confocal and STED, nuclei in blue). Confocal. N &#x3d; 2, <italic>n</italic> &#x3d; 1 (scale bar 10&#xa0;&#xb5;m), STED; N &#x3d; 1, <italic>n</italic> &#x3d; 1 (scale bar 5&#xa0;&#xb5;m).</p>
</caption>
<graphic xlink:href="fddev-03-1221628-g004.tif"/>
</fig>
<p>Taken together, these data show that penetramax elicits a selective, rapid, and transient widening of the bicellular and tricellular space, while the effect of EGTA is slower-acting and without size selectivity, but rapidly reversible.</p>
</sec>
<sec id="s3-4">
<title>3.4 Penetramax and EGTA exposure modulate epithelial TJ proteins differently</title>
<p>To further understand the molecular events originating from exposure of Caco-2 cell monolayers to penetramax and EGTA, the localization of ZO-1, occludin, tric, and selected claudins (cldns) were investigated (<xref ref-type="fig" rid="F5">Figure 5</xref>; <xref ref-type="fig" rid="F6">6</xref>; <xref ref-type="sec" rid="s11">Supplementary Figures S3&#x2013;S5</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Penetramax alters the TJ morphology, resulting in widening of the bTJs and tTJs, while EGTA induces translocation of TJs intracellularly. Upon recovery, both bTJs and tTJs are closed after penetramax exposure, whereas TJs are not localized on the apical functional network after EGTA exposure. Representative immunofluorescence microscopy images as maximum intensity projections for ZO-1, occludin, and tric after exposure for 3&#xa0;h (top rows) and after recovery (bottom rows) for penetramax (left columns) and EGTA (right columns). bTJ and tTJ in green, nuclei in blue. N &#x3d; 3, <italic>n</italic> &#x3d; 1 for penetramax N &#x3d; 2&#x2013;3, <italic>n</italic> &#x3d; 1 for EGTA. Scale bar &#x3d; 10&#xa0;&#xb5;m.</p>
</caption>
<graphic xlink:href="fddev-03-1221628-g005.tif"/>
</fig>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Penetramax exposure induces reorganization of the TJ network by an increase in cldn-2 and decrease in cldn-4 presence in the apical membrane whereas EGTA leads to cytosolic localization of cldn-2 and -4. Representative immunofluorescence microscopy images as maximum intensity projections for cldn-2 and -4 after exposure of 3&#xa0;h (top rows) and after recovery (bottom rows) for penetramax (left columns) and EGTA (right columns). Cldns in green, nuclei in blue. N &#x3d; 2&#x2013;3, <italic>n</italic> &#x3d; 1. Scale bar &#x3d; 10&#xa0;&#xb5;m.</p>
</caption>
<graphic xlink:href="fddev-03-1221628-g006.tif"/>
</fig>
<p>Immunostaining of ZO-1 revealed alterations in the cell-cell contact morphology upon exposure to penetramax concentrations higher than 25&#xa0;&#xb5;M (<xref ref-type="fig" rid="F5">Figure 5</xref>, row 1; <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). Most notably, a widening in the paracellular space of the bTJs and a ruffled TJ morphology were observed after exposure to penetramax concentrations of 55&#xa0;&#xb5;M or higher. Likewise, the occludin immunostaining (<xref ref-type="fig" rid="F5">Figure 5</xref>, row 3) revealed a ruffled TJ morphology after exposure to 55&#xa0;&#xb5;M penetramax (magnified). At higher concentrations, occludin was observed in the nucleus and was reduced in the TJ complex (<xref ref-type="fig" rid="F5">Figure 5</xref>, row 3; <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). The effects of penetramax on tTJs were assessed based on the localization of tric (<xref ref-type="fig" rid="F5">Figure 5</xref>, row 5). Exposure to concentrations higher than 25&#xa0;&#xb5;M penetramax showed widening of tTJs (<xref ref-type="fig" rid="F5">Figure 5</xref>, row 1, magnified for 55&#xa0;&#xb5;M).</p>
<p>We next addressed the cldn localization (<xref ref-type="fig" rid="F6">Figure 6</xref>). Exposure to penetramax for 3&#xa0;h induced redistribution of cldn-2, -4, and -7, but not of cldn-1 (<xref ref-type="fig" rid="F6">Figure 6</xref>; <xref ref-type="sec" rid="s11">Supplementary Figures S4, S5</xref>). Cldn-2 localized both intracellularly and in the TJ complex, especially after exposure to 95&#xa0;&#xb5;M penetramax (<xref ref-type="fig" rid="F6">Figure 6</xref>, row 1). Cldn-4 localized in tTJs to a greater extent upon exposure to 55&#xa0;&#xb5;M penetramax when compared to the buffer exposed cell monolayers, whereas at 95&#xa0;&#xb5;M penetramax, cldn-4 tended to internalize into the cytosol (<xref ref-type="fig" rid="F6">Figure 6</xref>, row 3).</p>
<p>Exposure to EGTA for 3&#xa0;h at concentrations exceeding 1&#xa0;mM altered the morphology of Caco-2 cell monolayers (<xref ref-type="fig" rid="F5">Figures 5</xref>, <xref ref-type="fig" rid="F6">6</xref>; <xref ref-type="sec" rid="s11">Supplementary Figures S3&#x2013;S5</xref>). A ruffled TJ morphology of the cell-cell contacts was observed at 7&#xa0;mM EGTA when stained against ZO-1 (<xref ref-type="fig" rid="F5">Figure 5</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). To that extent, intracellular localization of ZO-1 and occludin was also observed at 3&#xa0;mM and 7&#xa0;mM EGTA, respectively (<xref ref-type="fig" rid="F5">Figure 5</xref>, rows 1 and 3). Further, an apparent widening of the paracellular space (<xref ref-type="fig" rid="F5">Figure 5</xref>, magnified) was observed at 3&#xa0;mM EGTA when stained against occludin. Lastly, tric and cldn-1, -2, -4 and -7 immunostainings revealed similarly altered phenotypes. A more dramatic loss of the TJ from the plasma membrane was observed at 7&#xa0;mM EGTA (<xref ref-type="fig" rid="F5">Figures 5</xref>, <xref ref-type="fig" rid="F6">6</xref>; <xref ref-type="sec" rid="s11">Supplementary Figures S3&#x2013;S5</xref>).</p>
<p>Upon a recovery phase, the modulation of the paracellular space induced by penetramax was restored. Cldn-4 and occludin relocalized to the TJ complex, yet the ruffled TJ morphology remained as seen in images of ZO-1 and occludin immunostainings. Similarly, cldn-1 and -2 immunostainings revealed signs of restoration yet to a lesser extent than the rest of the investigated TJ proteins for the highest penetramax concentration (<xref ref-type="fig" rid="F6">Figure 6</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S4</xref>). Lastly, tric was found intracellularly in addition to its presence in tTJs. In contrast, after the recovery phase following EGTA exposure, the modulation of the paracellular space was not similarly restored. The TJs network was absent in some cells as shown when stained against ZO-1 while, cldn-1, -2, -4, and -7 along with tric were found intracellularly and still lost from the plasma membrane (<xref ref-type="fig" rid="F5">Figures 5</xref>, <xref ref-type="fig" rid="F6">6</xref>; <xref ref-type="sec" rid="s11">Supplementary Figures S3&#x2013;S5</xref>). Lastly, the paracellular space remained open as seen in cells stained against occludin (<xref ref-type="fig" rid="F5">Figure 5</xref>, row 4, 7&#xa0;mM EGTA).</p>
<p>To complement the immunostaining study on localization of the bTJ and tTJ in the cell monolayers, their expression levels were determined. Immunoblot analysis showed that exposure to penetramax was accompanied by a significant concentration-dependent reduction in the overall expression of ZO-1, occludin, cldn-1, and the barrier-forming cldn-4, and -7 (<xref ref-type="fig" rid="F7">Figures 7A, B</xref>). The highest effects were observed after 95&#xa0;&#xb5;M penetramax exposure with 77%, 58%, 25%, 66% and 71% reduction for ZO-1, occludin, cldn-1, -4 and -7, respectively. In contrast, expressions of tric and the pore-forming cldn-2 were increased by a factor of 2.0, 3.1, 2.0 and 1.8, 2.8, and 2.2 after exposure to 55, 75, and 95&#xa0;&#xb5;M penetramax, respectively (<xref ref-type="fig" rid="F7">Figures 7A, B</xref>). Upon recovery, the expression of the investigated TJ proteins overall returned to baseline values (<xref ref-type="fig" rid="F7">Figures 7D, E</xref>), except for ZO-1 that increased 3.4- and 1.7-fold in cells exposed to 75 and 95&#xa0;&#xb5;M penetramax, respectively along with signs of cldn-2 downregulation.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Penetramax alters the expression of TJs upon 3&#xa0;h of exposure whereas EGTA effects are observed upon recovery. Representative immunoblots of the expression of cldn-1, -2, -4, -7, ZO-1, occludin, and tric after <bold>(A)</bold> 3&#xa0;h of exposure followed by the relative expression of <bold>(B)</bold> penetramax and <bold>(C)</bold> EGTA after 3&#xa0;h of exposure and after <bold>(D)</bold> recovery followed by the relative expression of <bold>(E)</bold> penetramax and <bold>(F)</bold> EGTA. N &#x3d; 2&#x2013;3, <italic>n</italic> &#x3d; 6&#x2013;12. Results are shown as mean &#xb1; SD. For quantification, densitometric intensities were normalized to &#xdf;-actin loading control displayed for each lane. &#x2a;) <italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.01.</p>
</caption>
<graphic xlink:href="fddev-03-1221628-g007.tif"/>
</fig>
<p>In contrast to penetramax, EGTA exposure altered only the expression of cldn-1 and cldn-4 after 3&#xa0;h exposure (<xref ref-type="fig" rid="F7">Figures 7A, C</xref>). Interestingly, after the recovery phase, the expression of tric, cldn-2, and cldn-4 increased to up to 3-fold higher levels than the buffer exposed cells, whereas cldn-1 expression remained decreased in samples exposed to 5 and 7&#xa0;mM EGTA along with a concentration-dependent decrease in expression of ZO-1 (<xref ref-type="fig" rid="F7">Figures 7D, F</xref>).</p>
<p>Taken together, these results illustrate how widening of the paracellular space induced by penetramax exposure is accompanied by immediate yet transient changes in the localization and expression of the tested TJ proteins. In contrast, EGTA exposure impaired the organization of the TJs after 3&#xa0;h of exposure and this was not restored upon recovery.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<p>Improved absorption of biopharmaceuticals across the tight epithelium of the gastrointestinal tract is pursued, among other strategies, by modulating TJ proteins for increasing paracellular permeation (<xref ref-type="bibr" rid="B34">Neuhaus et al., 2018</xref>; <xref ref-type="bibr" rid="B6">Bocsik et al., 2019</xref>). In this study, we compared head-to-head the membrane-interacting peptide, penetramax, with the small-molecule and divalent cation chelator, EGTA, as PEs for oral peptide delivery. Specifically, epithelial integrity kinetics in real time, TJ protein expression and localization, and the overall ultrastructure of epithelial cell monolayers after excipient exposure and upon recovery were investigated along with permeability studies to understand the underlying mechanisms related to efficacy and safety of these excipients.</p>
<sec id="s4-1">
<title>4.1 Penetramax exerts specific effects on expression and localization of different TJ proteins</title>
<p>We have previously hypothesized that penetramax acts on TJ proteins due to significant decreases in TEER and corresponding increases in paracellular marker permeation across epithelium exposed to penetramax (<xref ref-type="bibr" rid="B13">Diedrichsen et al., 2021</xref>). Our results here demonstrate that penetramax exerts an immediate, transient, and reversible widening of the paracellular space between the enterocytes. This is associated with contraction of the actin cytoskeleton, regulation of specific TJ protein expressions, and changes in their localization. As a result of penetramax exposure, the expression of tric and cldn-2, a classified pore-forming cldn, were upregulated and localized in the cell membrane and cytoplasm, whereas the expression of cldn-4 and -7, classified as cation and anion barrier-forming cldns (<xref ref-type="bibr" rid="B51">Weber and Turner, 2017</xref>), respectively, along with the expression of ZO-1 and occludin were downregulated. The downregulated TJ proteins were generally removed from the plasma membrane, suggesting a remodeling of the function of the TJ protein network, observed both in the bTJ and tTJ (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F4">4</xref>, <xref ref-type="fig" rid="F6">6</xref>). While Krug et al. (<xref ref-type="bibr" rid="B25">Krug et al., 2009</xref>; <xref ref-type="bibr" rid="B26">Krug, 2017</xref>) showed that downregulation of tric lead to increased macromolecule permeation through tTJs, penetramax exposure increased macromolecule permeation along with upregulating tric expression, demonstrating that different modulations of this tTJ protein can result in increased membrane permeability. Watson et al. (<xref ref-type="bibr" rid="B49">Watson et al., 2001</xref>) and Van Itallie et al. (<xref ref-type="bibr" rid="B46">Van Itallie and Anderson, 2006</xref>) showed that upregulation of cldn-2 expression correlated with an increase in the diameter of the size- and ion-selective pore pathway (<xref ref-type="bibr" rid="B51">Weber and Turner, 2017</xref>), while overexpression of cldn-1, -4, and -7 decrease the diameter and subsequently, the overall paracellular permeation due to their proposed sealing properties (<xref ref-type="bibr" rid="B29">Le et al., 2021</xref>). On the contrary, the leak pathway allows the passage of macromolecules due to the contraction of actin cytoskeleton to a higher degree than the pore pathway (<xref ref-type="bibr" rid="B33">Monaco et al., 2021</xref>). Here, the penetramax-mediated modulation of the actin cytoskeleton and TJ proteins, resulting in size-selective permeation of the paracellular markers of FD4 and FD10 (<xref ref-type="fig" rid="F3">Figure 3</xref>), as the P<sub>app</sub> values for FD10 at all tested penetramax concentrations were lower than those for FD4. Previous work display that the enhanced permeation of FD4 by penetramax to a reasonable extent resembles the effect on insulin permeation, although the latter is slightly lower (<xref ref-type="bibr" rid="B13">Diedrichsen et al., 2021</xref>; <xref ref-type="bibr" rid="B14">Diedrichsen et al., 2023</xref>), likely due to differences in molecular weight, structure, and net charge. The observed permeation enhancement can be attributed to penetramax-induced TJ remodeling towards the leak pathway since cldn-2 is upregulated while cldn-4 and -7 is downregulated. The transient effect of penetramax during exposure is likely due to its peptidic nature and susceptibility to degradation. In contrast to penetramax, the amphipathic cell-penetrating peptide PN159, which was proposed to be a TJ-modulating peptide by Bocsik et al<italic>.</italic> (<xref ref-type="bibr" rid="B6">Bocsik et al., 2019</xref>), also resulted in an immediate reduction in TEER, but its effect was not transient during exposure as for penetramax, and TEER reversed only after medium exchange (<xref ref-type="bibr" rid="B6">Bocsik et al., 2019</xref>; <xref ref-type="bibr" rid="B39">Saaber and Reichl, 2019</xref>). In addition, PN159 exposure did not result in a size-selective passage of paracellular markers as similar permeation rates for FD4, FD10, and FD20 were determined. This was interpreted as a mechanism involving transcellular perturbation by Maher et al. (<xref ref-type="bibr" rid="B32">Maher et al., 2019</xref>). Our results with penetramax show increased TEER upon recovery along with morphological changes in terms of fewer, shorter, and flatter cells in the monolayer (<xref ref-type="fig" rid="F5">Figures 5</xref>, <xref ref-type="fig" rid="F6">6</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>). However, the expression of the TJ proteins was reversible upon recovery. Thus, the membrane-interacting properties of cell-penetrating peptides (<xref ref-type="bibr" rid="B23">Kamei et al., 2013b</xref>; <xref ref-type="bibr" rid="B42">Shi et al., 2014</xref>) and resulting rapid effects reported here contrast with the required 12-48&#xa0;h pre-exposure of other peptides described as TJ modulating peptides, such as angubindin-1 and trictide (<xref ref-type="bibr" rid="B12">Cording et al., 2017</xref>; <xref ref-type="bibr" rid="B27">Krug et al., 2017</xref>).</p>
</sec>
<sec id="s4-2">
<title>4.2 Non-specific and time-dependent modulation of TJs by EGTA</title>
<p>EGTA is a well-known Ca<sup>2&#x2b;</sup> chelator and modulates the cytoskeleton and the TJ protein network either directly via extracellular depletion of Ca<sup>2&#x2b;</sup> or by shifting the extra-to intercellular Ca<sup>2&#x2b;</sup> balance (<xref ref-type="bibr" rid="B36">Raiman et al., 2003</xref>). Further understanding how EGTA affects TJ and cytoskeleton dynamics and thereby acts as a PE is lacking regardless that its analog EDTA is a constituent in the POD&#x2122; technology investigated for oral peptide delivery (<xref ref-type="bibr" rid="B54">Zizzari et al., 2021</xref>). We showed here that EGTA induced a gradual and concentration-dependent decrease in epithelial barrier properties during exposure, as determined by TEER measurements (<xref ref-type="fig" rid="F3">Figure 3</xref>). Our results suggest that the chelation of divalent cations results in heterogeneous effects across the monolayer, as previously demonstrated by Tria et al. (<xref ref-type="bibr" rid="B44">Tria et al., 2013</xref>). This is supported by the observations by Richter et al. (<xref ref-type="bibr" rid="B37">Richter et al., 2016</xref>), who suggested epithelial hot spots for macromolecular permeation induced by EGTA. Importantly, we did not deplete the experimental buffer in terms of divalent cations to better resemble <italic>in vivo</italic> conditions, which contrasts with earlier studies that used Ca<sup>2&#x2b;</sup> and Mg<sup>2&#x2b;</sup> depleted media when investigating EGTA and EDTA as permeation enhancers (<xref ref-type="bibr" rid="B18">Farshori and Kachar, 1999</xref>). The buffer contained 1&#xa0;mM Ca<sup>2&#x2b;</sup> and 0.9&#xa0;mM&#xa0;Mg<sup>2&#x2b;</sup> leading to complexation of nearly all Ca<sup>2&#x2b;</sup> ions at the 1&#xa0;mM EGTA concentration due to a 1:1&#xa0;M binding ratio and preferential Ca<sup>2&#x2b;</sup> over Mg<sup>2&#x2b;</sup> binding (<xref ref-type="bibr" rid="B11">Caldwell and Cuthbert, 1970</xref>). At the higher EGTA concentrations, all divalent cations are bound in an EGTA complex and as such depleted from the buffer. Correspondingly, our data showed less TEER reduction than previously reported (<xref ref-type="bibr" rid="B18">Farshori and Kachar, 1999</xref>; <xref ref-type="bibr" rid="B31">Ma et al., 2000</xref>; <xref ref-type="bibr" rid="B38">Rothen-Rutishauser et al., 2002</xref>; <xref ref-type="bibr" rid="B53">Yu et al., 2013</xref>; <xref ref-type="bibr" rid="B39">Saaber and Reichl, 2019</xref>). It is interesting, that despite an apparent disruption of the TJs following exposure to EGTA (<xref ref-type="fig" rid="F2">Figure 2</xref>), the TEER rapidly returned to baseline levels after removal of EGTA (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Epithelial reorganization and/or unaffected cells may compensate for this. For all TJ proteins investigated, a subpopulation of cells (<xref ref-type="sec" rid="s11">Supplementary Figures S3&#x2013;S5</xref>), in which TJ proteins were localized intracellularly, demonstrated that divalent cation depletion resulted in loss of TJ proteins from the plasma membrane. Following exposure to EGTA, only cldn-1 and -4 showed a significant decrease in expression, thus suggesting their importance for Ca<sup>2&#x2b;</sup> regulation. While penetramax had a more significant effect on the permeation of FD4 than that of FD10, EGTA did not show such size selectivity (<xref ref-type="fig" rid="F3">Figures 3F&#x2013;H</xref>), possibly due to its clearly different effect on the paracellular space despite overall similar TEER levels were determined. Regulation of TJ protein expression occurred during the recovery period after EGTA exposure as revealed by the upregulation of cldn-2, -4, and tric. In addition to this, the localization of all the investigated TJ proteins suggests that the reconstitution mechanism within the Caco-2 cell monolayers after EGTA exposure relies on their <italic>de novo</italic> protein synthesis, implying a longer time required for the recovery (re-epithelization) process in comparison to what was observed after exposure to penetramax.</p>
</sec>
<sec id="s4-3">
<title>4.3 Reversibility of epithelial barrier integrity after excipient exposure</title>
<p>The role of the actin cytoskeleton and the TJ dynamics in intestinal epithelial regeneration after excipient exposure is poorly understood. The present study aimed to elucidate the underlying mechanism(s) involved in epithelial barrier effects and recovery.</p>
<p>Penetramax reduced epithelial tightness resulting in a transient loss of cell polarity (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref ref-type="sec" rid="s11">Supplementary Figures S1, S2</xref>) and a partial mesenchymal phenotype (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>). Previous studies have addressed alterations in cell morphology and apical-basal polarity (<xref ref-type="bibr" rid="B17">Du et al., 2010</xref>), remodeling of the TJs (<xref ref-type="bibr" rid="B5">Balda and Matter, 2016</xref>), and induction of cell motility (<xref ref-type="bibr" rid="B52">Yan et al., 2010</xref>; <xref ref-type="bibr" rid="B21">Jiang et al., 2018</xref>; <xref ref-type="bibr" rid="B15">Dongre and Weinberg, 2019</xref>) as part of epithelial-to-mesenchymal transition that occurs during epithelial recovery. Such events were observed after exposure to penetramax as part of the re-epithelialization process. This may explain the observation of stress fibers, essential actin-based components for cellular contractility, migration, and adhesion (<xref ref-type="bibr" rid="B19">Gaston et al., 2021</xref>; <xref ref-type="bibr" rid="B30">Lehtim&#xe4;ki et al., 2021</xref>), after cytoskeletal re-organization (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Interestingly, after the recovery period following EGTA exposure, the barrier was still compromised as TJ proteins were not localized in the apical-lateral TJ network (e.g., ZO-1) and F-actin disassembly was evident (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F5">5</xref>). Like what was observed after exposure to penetramax, the cellular volume after EGTA exposure was smaller than that of cells exposed to buffer (<xref ref-type="sec" rid="s11">Supplementary Figures S1, S2</xref>), likely a result of divalent cation depletion and its effect on the cytoskeletal network.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s5">
<title>5 Conclusion</title>
<p>In the present study, we demonstrate that the modulation of dynamic properties of the intestinal epithelial barrier is dependent on the excipient type. Penetramax exposure resulted in a fast, transient, and size-selective widening of the paracellular space that corresponded to a transient TJ remodeling. In contrast, EGTA resulted in a gradual and time-dependent effect that was not reflected in TJ protein expression levels and delayed the TJ re-localization to the plasma membrane for sealing the paracellular space. However, it was clear that independently of the excipient type, the TJ modulation events are linked to a transient decrease in cell polarity. Overall, understanding TJ modulation and cytoskeleton dynamics in well-differentiated epithelia may lead to better understanding of parameters relevant for selection of excipients, such as PEs that are desired to rapidly and in a controlled, specific, and reversible manner exert the desired effect leading to selective improved absorption of the biopharmaceutical in question. From this perspective, and based on our findings, penetramax seems to be superior to EGTA. More detailed understanding of cellular responses to PEs will guide the selection of excipients suitable for use in oral peptide delivery.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>Conceptualization: DP, MK, HN, Data curation: DP Formal analysis: DP, MK, HN, Funding acquisition: HN, Investigation: DP, MK, HN, Methodology: DP, MK, HN, Project administration: HN, Resources: HN, Software: HN, Supervision: SP, MK, HN, Validation: DP, MK, HN, Visualization: DP, SP, MK, HN, Roles/writing: DP-original draft, Writing review and editing: DP, MK, SP, HN. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>The Novo Nordisk Foundation is acknowledged for funding the project (Grand Challenge Program NNF16OC0021948 through the Center for Biopharmaceuticals and Biobarriers in Drug Delivery (BioDelivery), UCPH). The Villum Fonden is acknowledged for funding of the CLARIOstar platereader (Villum Young Investigator Grant, 19175).</p>
</sec>
<ack>
<p>The Core Facility of Integrated Microscopy, Faculty of Health and Medical Sciences, University of Copenhagen is acknowledged for providing access to microscopes. Application Specialist Pablo Hernandez Varas for assistance with STED, confocal, and general feedback, Application Specialist Thomas Hartig Braunstein for assistance with confocal, Application Specialist Tillmann Pape and Professor Klaus Qvortrup for assistance with TEM, and Technician Zhila Nikrozi for TEM sample preparation. Lastly, Associate Professor Marco van de Weert for proofreading and feedback.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The authors MK and HN declared that they were editorial board members of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fddev.2023.1221628/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fddev.2023.1221628/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.DOCX" id="SM1" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.PNG" id="SM2" mimetype="application/PNG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<sec id="s12">
<title>Abbreviations</title>
<p>bTJ, bicellular TJ; Caco-2, colorectal adenocarcinoma cell line; cldn, claudin; CLSM, confocal laser scanning microscopy; EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic acid; F-actin, filamentous actin; FD, stimulation emission depletion microscopy; FITC-dextran; MCFA, medium chain fatty acid; PE, permeation enhancer; STED, stimulation emission depletion microscopy; TEER, transepithelial electrical resistance; TEM, transmission electron microscopy; TJ, tight junction; tric, tricellulin; tTJ, tricellular TJ; ZO, zonula occludens.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aigouy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mirouse</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>ScientiFig: a tool to build publication-ready scientific figures</article-title>. <source>Nat. Methods</source> <volume>10</volume> (<issue>11</issue>), <fpage>1048</fpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2692</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Van Itallie</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Physiology and function of the tight junction</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>1</volume> (<issue>2</issue>), <fpage>a002584</fpage>. <comment>PMID: 20066090; PMCID: PMC2742087</comment>. <pub-id pub-id-type="doi">10.1101/cshperspect.a002584</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apostolou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Panchakshari</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Manatakis</surname>
<given-names>D. V.</given-names>
</name>
<name>
<surname>Paraskevopoulou</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Luc</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A novel microphysiological colon platform to decipher mechanisms driving human intestinal permeability</article-title>. <source>Cell Mol. Gastroenterol. Hepatol.</source> <volume>12</volume> (<issue>5</issue>), <fpage>1719</fpage>&#x2013;<lpage>1741</lpage>. <comment>Epub 2021 Jul 17. PMID: 34284165; PMCID: PMC8551844</comment>. <pub-id pub-id-type="doi">10.1016/j.jcmgh.2021.07.004</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Artursson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lundquist</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A new opening for orally taken peptide drugs</article-title>. <source>Nat. Biomed. Eng.</source> <volume>4</volume>, <fpage>12</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/s41551-019-0513-1</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balda</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Matter</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Tight junctions as regulators of tissue remodelling</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>42</volume>, <fpage>94</fpage>&#x2013;<lpage>101</lpage>. <comment>Epub 2016 May 26. PMID: 27236618</comment>. <pub-id pub-id-type="doi">10.1016/j.ceb.2016.05.006</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bocsik</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gr&#xf3;f</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>&#xd6;tv&#xf6;s</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zs&#xed;ros</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Daruka</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Dual Action of the PN159/KLAL/MAP Peptide: increase of drug penetration across Caco-2 intestinal barrier model by modulation of tight junctions and plasma membrane permeability</article-title>. <source>Pharmaceutics</source> <volume>11</volume> (<issue>2</issue>), <fpage>73</fpage>. <comment>PMID: 30744154; PMCID: PMC6410202</comment>. <pub-id pub-id-type="doi">10.3390/pharmaceutics11020073</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bocsik</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>F. R.</given-names>
</name>
<name>
<surname>Gyebrovszki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>F&#xfc;l&#xf6;p</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Blasig</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dabrowski</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Reversible opening of intercellular junctions of intestinal epithelial and brain endothelial cells with tight junction modulator peptides</article-title>. <source>J. Pharm. Sci.</source> <volume>105</volume> (<issue>2</issue>), <fpage>754</fpage>&#x2013;<lpage>765</lpage>. <comment>PMID: 26869428</comment>. <pub-id pub-id-type="doi">10.1016/j.xphs.2015.11.018</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brayden</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Evolving peptides for oral intake</article-title>. <source>Nat. Biomed. Eng.</source> <volume>4</volume> (<issue>5</issue>), <fpage>487</fpage>&#x2013;<lpage>488</lpage>. <comment>PMID: 32393890</comment>. <pub-id pub-id-type="doi">10.1038/s41551-020-0559-0</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Mitragotri</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Materials for oral delivery of proteins and peptides</article-title>. <source>Nat. Rev. Mater</source> <volume>5</volume>, <fpage>127</fpage>&#x2013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1038/s41578-019-0156-6</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buckley</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>B&#xe6;kdal</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Vegge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maarbjerg</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Pyke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ahnfelt-R&#xf8;nne</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist</article-title>. <source>Sci. Transl. Med.</source> <volume>10</volume> (<issue>467</issue>), <fpage>eaar7047</fpage>. <comment>PMID: 30429357</comment>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aar7047</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Caldwell</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>1970</year>). &#x201c;<article-title>Calcium chelation and buffers</article-title>,&#x201d; in <source>A Symposium on calcium and cellular function</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Cuthbert</surname>
<given-names>A. W.</given-names>
</name>
</person-group> (<publisher-loc>London</publisher-loc>: <publisher-name>palgrave Macmillan UK</publisher-name>), <fpage>10</fpage>&#x2013;<lpage>16</lpage>.</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cording</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arslan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Staat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dithmer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krug</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Kr&#xfc;ger</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Trictide, a tricellulin-derived peptide to overcome cellular barriers</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>1405</volume> (<issue>1</issue>), <fpage>89</fpage>&#x2013;<lpage>101</lpage>. <comment>Epub 2017 Jun 20. PMID: 28633193</comment>. <pub-id pub-id-type="doi">10.1111/nyas.13392</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diedrichsen</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Harloff-Helleberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Besenius</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leberer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Revealing the importance of carrier-cargo association in delivery of insulin and lipidated insulin</article-title>. <source>J. Control Release</source> <volume>338</volume>, <fpage>8</fpage>&#x2013;<lpage>21</lpage>. <comment>Epub 2021 Jul 21. PMID: 34298056</comment>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.07.030</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diedrichsen</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Tuelung</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Foder&#xe0;</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>H. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Stereochemistry and intermolecular interactions influence carrier peptide-mediated insulin delivery</article-title>. <source>Mol. Pharm.</source> <volume>20</volume> (<issue>2</issue>), <fpage>1202</fpage>&#x2013;<lpage>1212</lpage>. <comment>Epub 2023 Jan 6. PMID: 36607603</comment>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00883</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dongre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>20</volume> (<issue>2</issue>), <fpage>69</fpage>&#x2013;<lpage>84</lpage>. <comment>PMID: 30459476</comment>. <pub-id pub-id-type="doi">10.1038/s41580-018-0080-4</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drucker</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Advances in oral peptide therapeutics</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>19</volume>, <fpage>277</fpage>&#x2013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0053-0</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>The tight junction protein, occludin, regulates the directional migration of epithelial cells</article-title>. <source>Dev. Cell</source> <volume>18</volume> (<issue>1</issue>), <fpage>52</fpage>&#x2013;<lpage>63</lpage>. <comment>PMID: 20152177</comment>. <pub-id pub-id-type="doi">10.1016/j.devcel.2009.12.008</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farshori</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kachar</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Redistribution and phosphorylation of occludin during opening and resealing of tight junctions in cultured epithelial cells</article-title>. <source>J. Membr. Biol.</source> <volume>170</volume>, <fpage>147</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1007/s002329900544</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaston</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Beco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Doss</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gauquelin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>D&#x2019;Alessandro</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>EpCAM promotes endosomal modulation of the cortical RhoA zone for epithelial organization</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>2226</fpage>. <comment>PMID: 33850145; PMCID: PMC8044225</comment>. <pub-id pub-id-type="doi">10.1038/s41467-021-22482-9</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonz&#xe1;lez-Mariscal</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Betanzos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Avila-Flores</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>MAGUK proteins: structure and role in the tight junction</article-title>. <source>Semin. Cell Dev. Biol.</source> <volume>11</volume> (<issue>4</issue>), <fpage>315</fpage>&#x2013;<lpage>324</lpage>. <comment>PMID: 10966866</comment>. <pub-id pub-id-type="doi">10.1006/scdb.2000.0178</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Epithelial-mesenchymal transition in Crohn&#x27;s disease</article-title>. <source>Mucosal Immunol.</source> <volume>11</volume> (<issue>2</issue>), <fpage>294</fpage>&#x2013;<lpage>303</lpage>. <comment>Epub 2017 Dec 20. PMID: 29346350</comment>. <pub-id pub-id-type="doi">10.1038/mi.2017.107</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamei</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takeda-Morishita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Terasawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2013a</year>). <article-title>Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps</article-title>. <source>J. Pharm. Sci.</source> <volume>102</volume> (<issue>2</issue>), <fpage>469</fpage>&#x2013;<lpage>479</lpage>. <comment>Epub 2012 Nov 18. PMID: 23160942</comment>. <pub-id pub-id-type="doi">10.1002/jps.23364</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamei</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Onuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takayama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takeda-Morishita</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013b</year>). <article-title>Mechanistic study of the uptake/permeation of cell-penetrating peptides across a caco-2 monolayer and their stimulatory effect on epithelial insulin transport</article-title>. <source>J. Pharm. Sci.</source> <volume>102</volume> (<issue>11</issue>), <fpage>3998</fpage>&#x2013;<lpage>4008</lpage>. <comment>Epub 2013 Aug 20. PMID: 23963728</comment>. <pub-id pub-id-type="doi">10.1002/jps.23708</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krug</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Amasheh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dittmann</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Christoffel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fromm</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Amasheh</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells</article-title>. <source>Biomaterials</source> <volume>34</volume> (<issue>1</issue>), <fpage>275</fpage>&#x2013;<lpage>282</lpage>. <comment>Epub 2012 Oct 12. PMID: 23069717</comment>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.09.051</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krug</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Amasheh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Milatz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>G&#xfc;nzel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>J. K.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability</article-title>. <source>Mol. Biol. Cell</source> <volume>20</volume> (<issue>16</issue>), <fpage>3713</fpage>&#x2013;<lpage>3724</lpage>. <comment>Epub 2009 Jun 17. PMID: 19535456; PMCID: PMC2777931</comment>. <pub-id pub-id-type="doi">10.1091/mbc.e09-01-0080</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krug</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Contribution of the tricellular tight junction to paracellular permeability in leaky and tight epithelia</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>1397</volume> (<issue>1</issue>), <fpage>219</fpage>&#x2013;<lpage>230</lpage>. <comment>Epub 2017 Jun 12. PMID: 28605032</comment>. <pub-id pub-id-type="doi">10.1111/nyas.13379</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krug</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Hayaishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iguchi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Watari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fromm</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Angubindin-1, a novel paracellular absorption enhancer acting at the tricellular tight junction</article-title>. <source>J. Control Release</source> <volume>260</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <comment>Epub 2017 May 18. PMID: 28528740</comment>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2017.05.024</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lau</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>M. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Therapeutic peptides: historical perspectives, current development trends, and future directions</article-title>. <source>Bioorg Med. Chem.</source> <volume>26</volume> (<issue>10</issue>), <fpage>2700</fpage>&#x2013;<lpage>2707</lpage>. <comment>Epub 2017 Jul 1. PMID: 28720325</comment>. <pub-id pub-id-type="doi">10.1016/j.bmc.2017.06.052</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mazahery</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>A. D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Regulation of intestinal epithelial barrier and immune function by activated T cells</article-title>. <source>Cell Mol. Gastroenterol. Hepatol.</source> <volume>11</volume> (<issue>1</issue>), <fpage>55</fpage>&#x2013;<lpage>76</lpage>. <comment>Epub 2020 Jul 11. PMID: 32659380; PMCID: PMC7596298</comment>. <pub-id pub-id-type="doi">10.1016/j.jcmgh.2020.07.004</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lehtim&#xe4;ki</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Rajakyl&#xe4;</surname>
<given-names>E. K.</given-names>
</name>
<name>
<surname>Tojkander</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lappalainen</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Generation of stress fibers through myosin-driven reorganization of the actin cortex</article-title>. <source>Elife</source> <volume>10</volume>, <fpage>e60710</fpage>&#x2013;<lpage>e60743</lpage>. <pub-id pub-id-type="doi">10.7554/eLife.60710</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hoa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Merryfield</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tarnawski</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement</article-title>. <source>Microsc. Res. Tech.</source> <volume>51</volume> (<issue>2</issue>), <fpage>156</fpage>&#x2013;<lpage>168</lpage>. <comment>PMID: 11054866</comment>. <pub-id pub-id-type="doi">10.1002/1097-0029(20001015)51:2&#x3c;156::AID-JEMT7&#x3e;3.0.CO;2-J</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maher</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brayden</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Casettari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Illum</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Application of permeation enhancers in oral delivery of macromolecules: an update</article-title>. <source>Pharmaceutics</source> <volume>11</volume>, <fpage>41</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics11010041</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monaco</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ovryn</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Axis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Amsler</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The epithelial cell leak pathway</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>14</issue>), <fpage>7677</fpage>. <comment>PMID: 34299297; PMCID: PMC8305272</comment>. <pub-id pub-id-type="doi">10.3390/ijms22147677</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neuhaus</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Piontek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Protze</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Eichner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mahringer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Subileau</surname>
<given-names>E. A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Reversible opening of the blood-brain barrier by claudin-5-binding variants of <italic>Clostridium perfringens</italic> enterotoxin&#x2019;s claudin-binding domain</article-title>. <source>Biomaterials</source> <volume>161</volume>, <fpage>129</fpage>&#x2013;<lpage>143</lpage>. <comment>Epub 2018 Feb 2. PMID: 29421550</comment>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.01.028</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noach</surname>
<given-names>A. B. J.</given-names>
</name>
<name>
<surname>Kurosaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Blom-Roosemalen</surname>
<given-names>M. C. M.</given-names>
</name>
<name>
<surname>De Boer</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Breimer</surname>
<given-names>D. D.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Cell-polarity dependent effect of chelation on the paracellular permeability of confluent Caco-2 cell monolayers</article-title>. <source>Inter J. Pharm.</source> <volume>90</volume>, <fpage>229</fpage>&#x2013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/0378-5173(93)90195-l</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raiman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>T&#xf6;rm&#xe4;lehto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yritys</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Junginger</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>M&#xf6;nkk&#xf6;nen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Effects of various absorption enhancers on transport of clodronate through Caco-2 cells</article-title>. <source>Int. J. Pharm.</source> <volume>261</volume> (<issue>1-2</issue>), <fpage>129</fpage>&#x2013;<lpage>136</lpage>. <comment>PMID: 12878401</comment>. <pub-id pub-id-type="doi">10.1016/s0378-5173(03)00300-4</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richter</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Schmauder</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Krug</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Gebert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schumann</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>A novel method for imaging sites of paracellular passage of macromolecules in epithelial sheets</article-title>. <source>J. Control Release</source> <volume>229</volume>, <fpage>70</fpage>&#x2013;<lpage>79</lpage>. <comment>Epub 2016 Mar 16. PMID: 26995760</comment>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2016.03.018</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothen-Rutishauser</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Riesen</surname>
<given-names>F. K.</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>G&#xfc;nthert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wunderli-Allenspach</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Dynamics of tight and adherens junctions under EGTA treatment</article-title>. <source>J. Membr. Biol.</source> <volume>188</volume> (<issue>2</issue>), <fpage>151</fpage>&#x2013;<lpage>162</lpage>. <comment>PMID: 12172640</comment>. <pub-id pub-id-type="doi">10.1007/s00232-001-0182-2</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saaber</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Reichl</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>A unified <italic>in vitro</italic> test system for the assessment of tight junction modulators</article-title>. <source>Eur. J. Pharm. Biopharm.</source> <volume>142</volume>, <fpage>353</fpage>&#x2013;<lpage>363</lpage>. <comment>Epub 2019 Jul 3. PMID: 31278992</comment>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2019.07.004</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rasband</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Eliceiri</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>NIH image to ImageJ: 25 years of image analysis</article-title>. <source>Nat. Methods</source> <volume>9</volume>, <fpage>671</fpage>&#x2013;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Tight junctions on the move: molecular mechanisms for epithelial barrier regulation</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>1258</volume>, <fpage>9</fpage>&#x2013;<lpage>18</lpage>. <comment>PMID: 22731710; PMCID: PMC3690943</comment>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06613.x</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>N. Q.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>X. R.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>A survey on &#x201c;trojan Horse&#x201d; peptides: opportunities, issues and controlled entry to troy</article-title>. <source>J. Control Release</source> <volume>194</volume>, <fpage>53</fpage>&#x2013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.08.014</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="web">
<collab>Study Record</collab> (<year>2023</year>). <article-title>Beta ClinicalTrials.gov</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/study/NCT04606576?term=NCT04606576">https://www.clinicaltrials.gov/study/NCT04606576?term&#x3d;NCT04606576</ext-link> (Accessed July 10, 2023)</comment>.</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tria</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jimison</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Hama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bongo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>R. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Sensing of EGTA mediated barrier tissue disruption with an organic transistor</article-title>. <source>Biosens. (Basel).</source> <volume>3</volume> (<issue>1</issue>), <fpage>44</fpage>&#x2013;<lpage>57</lpage>. <comment>PMCID: PMC3930842</comment>. <pub-id pub-id-type="doi">10.3390/bios3010044</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Itallie</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Architecture of tight junctions and principles of molecular composition</article-title>. <source>Semin. Cell Dev. Biol.</source> <volume>36</volume>, <fpage>157</fpage>&#x2013;<lpage>165</lpage>. <comment>Epub 2014 Aug 27. PMID: 25171873; PMCID: PMC4254347</comment>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2014.08.011</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Itallie</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Claudins and epithelial paracellular transport</article-title>. <source>Annu. Rev. Physiol.</source> <volume>68</volume>, <fpage>403</fpage>&#x2013;<lpage>429</lpage>. <comment>PMID: 16460278</comment>. <pub-id pub-id-type="doi">10.1146/annurev.physiol.68.040104.131404</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Itallie</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Fanning</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Bridges</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton</article-title>. <source>Mol. Biol. Cell</source> <volume>20</volume> (<issue>17</issue>), <fpage>3930</fpage>&#x2013;<lpage>3940</lpage>. <comment>Epub 2009 Jul 15. PMID: 19605556; PMCID: PMC2735491</comment>. <pub-id pub-id-type="doi">10.1091/mbc.e09-04-0320</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Biopharmaceutical benchmarks 2018</article-title>. <source>Nat. Biotechnol.</source> <volume>36</volume> (<issue>12</issue>), <fpage>1136</fpage>&#x2013;<lpage>1145</lpage>. <comment>PMID: 30520869</comment>. <pub-id pub-id-type="doi">10.1038/nbt.4305</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Warhurst</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers</article-title>. <source>Am. J. Physiol. Cell Physiol.</source> <volume>281</volume> (<issue>2</issue>), <fpage>C388</fpage>&#x2013;<lpage>C397</lpage>. <comment>PMID: 11443038</comment>. <pub-id pub-id-type="doi">10.1152/ajpcell.2001.281.2.C388</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Dynamic properties of the tight junction barrier</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>1257</volume>, <fpage>77</fpage>&#x2013;<lpage>84</lpage>. <comment>PMID: 22671592; PMCID: PMC3687038</comment>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06528.x</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Dynamic modeling of the tight junction pore pathway</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>1397</volume> (<issue>1</issue>), <fpage>209</fpage>&#x2013;<lpage>218</lpage>. <comment>Epub 2017 Jun 12. PMID: 28605031; PMCID: PMC5488723</comment>. <pub-id pub-id-type="doi">10.1111/nyas.13374</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>W. A.</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Travis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2</article-title>. <source>Am. J. Pathol.</source> <volume>176</volume> (<issue>5</issue>), <fpage>2247</fpage>&#x2013;<lpage>2258</lpage>. <comment>Epub 2010 Mar 19. PMID: 20304956; PMCID: PMC2861090</comment>. <pub-id pub-id-type="doi">10.2353/ajpath.2010.090048</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>The effect of various absorption enhancers on tight junction in the human intestinal Caco-2 cell line</article-title>. <source>Drug Dev. Ind. Pharm.</source> <volume>39</volume> (<issue>4</issue>), <fpage>587</fpage>&#x2013;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.3109/03639045.2012.692376</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zizzari</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Pliatsika</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gall</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Riedl</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>New perspectives in oral peptide delivery</article-title>. <source>Drug Discov. Today</source> <volume>26</volume> (<issue>4</issue>), <fpage>1097</fpage>&#x2013;<lpage>1105</lpage>. <comment>Epub 2021 Jan 23. PMID: 33497830</comment>. <pub-id pub-id-type="doi">10.1016/j.drudis.2021.01.020</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>